immune function marker does not predict benefit of trastuzumab in her breast cancer patients
Published 9 years ago • 1.2K plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
4:15
identifying genes that can predict if breast cancer drug is working - mayo clinic
-
4:26
altto trials findings for treating her2 breast cancer - mayo clinic
-
2:36
pten and herceptin study - mayo clinic
-
6:05
her2 study
-
6:31
ah-ha moment leads to new breast cancer tumor testing standards - mayo clinic
-
3:00
genes may predict trastuzumab outcomes in breast cancer
-
1:23
mayo clinic researchers find survival improves when herceptin is used with chemotherapy
-
28:08
innovations in breast cancer research
-
29:24
harness your immune system to fight cancer - living with cancer symposium 2017
-
5:04
immunotherapy and triple negative breast cancer - mayo clinic
-
4:54
master “cut-off switch” for cancer-causing her2 protein located.
-
1:36
dr. perez discusses obesity as a predictive marker
-
7:36
asco 2022: metastatic breast cancer drug therapy recap
-
1:21
dr. park on the benefit of trastuzumab deruxtecan in her2 breast cancer
-
3:58
promise breast cancer clinical trial
-
6:24
mayo clinic receives federal grant for clinical test of triple-negative breast cancer vaccine
-
1:16
dr. perez discusses a genomic analysis of the ncctg (alliance) n9831 adjuvant trastuzumab trial
-
4:31
study of atezolizumab with pertuzumab and trastuzumab in her2- positive metastatic breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg